Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01010399 · ClinicalTrials.gov registry record · Phase 4

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

A Phase 4 study of HIV Infection and Hypertriglyceridemia, sponsored by Felizarta, Franco, M.D..

Completed
Registry status
Phase 4
Development phase
36
Enrollment target
1
Study location

NCT01010399: Completed Phase 4 study of HIV Infection and Hypertriglyceridemia, sponsored by Felizarta, Franco, M.D..

NCT01010399 is a Phase 4 study of HIV Infection and Hypertriglyceridemia that has completed, run by Felizarta, Franco, M.D.. The registered enrollment target is 36 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01010399, a Phase 4 study of HIV Infection and Hypertriglyceridemia, has completed, sponsored by Felizarta, Franco, M.D..

COMPLETED
Registry status
Phase 4
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dL while maintaining virologic suppression.

Conditions Studied

HIV Infection Hypertriglyceridemia

Interventions

  • DIETARY_SUPPLEMENT Lovaza
  • DRUG fosamprenavir/ritonavir

Study Locations (1)

California

  • Franco Felizarta, MD - Bakersfield

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2009-09
Est. Completion 2010-11
Phase Phase 4
Felizarta, Franco, M.D.

1 total trials

What the finished NCT01010399 record still lists

NCT01010399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which Lovaza is the first listed.

NCT01010399 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01010399 about?

NCT01010399 is a clinical study titled "Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects". In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dL while maintaining virologic suppressi...

What is the current status of trial NCT01010399?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2009-09. Estimated completion is 2010-11.

What conditions does trial NCT01010399 study?

This clinical trial studies the following conditions: HIV Infection, Hypertriglyceridemia.

What interventions are being tested in trial NCT01010399?

The interventions under investigation include: Lovaza (DIETARY_SUPPLEMENT), fosamprenavir/ritonavir (DRUG).

Who is sponsoring clinical trial NCT01010399?

This trial is sponsored by Felizarta, Franco, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01010399 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01010399's enrollment target sits among peer trials

36 49th of 73 higher than 22 of 73 other HIV Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01010399, the US trial registry maintained by the National Library of Medicine. NCT01010399 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.